Genentech
A Member of the Roche Group

2021 Independent Medical Education
Call for Grant Notification

Issue Date: **November 8, 2021**

The *Independent Medical Education team at Genentech, a member of the Roche Group,* invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech CGNs are made available through our online Genentech Funding Request System (gFRS) site (http://funding.gene.com) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp) and the Society for Academic Continuing Medical Education (SACME). *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions
1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on http://funding.gene.com)
2. This CGN does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reasons, and in fairness to all providers, all communications about this CGN must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this CGN may result in a denial.

Instructions

Eligibility Criteria	- U.S. based education provider - Registered account in gFRS - Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Deadlines

Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this CGN have 3 weeks to <u>submit full grant application(s)</u> online through funding.gene.com (gFRS).
	
	When submitting the application, please be sure to:
	    ▪ Select the Therapeutic Area (**Oncology**) and Disease State (**Pan Tumor**).
	    ▪ Include "**CGN Nov 2021**" in the program title of the grant.
		November 29, 2021

Step 2	Grant decisions will be communicated to the accredited educational provider through gFRS.	December 6, 2021

<u>Additional Considerations</u>
Provider(s) who are awarded grants are encouraged but not required to:
1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or patient outcomes improvement as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Genentech
A Member of the Roche Group

Currently Available CGN Focus Area:

Focus	Opportunity
Therapeutic Area: Oncology **Learning Audience:** Oncologists Nurse Practitioners Physician's Assistants Nurses Pharmacists Oncology Multi-Disciplinary Teams **Support Available:** Up to $200,000 Knowledge- and Competence-based National and Regional Education *(Understanding & addressing national or local gaps and emerging data)*	The introduction of immune checkpoint inhibitors has provided new approaches to treating a number of cancers in recent years, and research continues to identify new molecular targets and seeks to better understand their potential role and applications in oncology. One such pathway currently being explored is TIGIT, T-cell immunoreceptor with Ig and ITIM domains, which is an inhibitory receptor expressed on multiple immune cells. TIGIT expression correlates with PD-1, especially in tumor-infiltrating T cells, and is often co-expressed on stem cell memory T cells. As new research comes to light exploring this pathway, we seek to support education that explains how this pathway functions and the potential role that inhibition of this pathway can play in the treatment of solid tumors. References: 1. Chauvin JM, Zarour HM. TIGIT in cancer immunotherapy. J Immunother Cancer. 2020 Sep;8(2):e000957 2. Harjunpää H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020;200(2):108-119 3. Manieri NA, Chiang EY, Grogan JL. TIGIT: a key inhibitor of the cancer immunity cycle. Trends Immunol. 2017;38(1):20-28